1-8 of 8
Connie E. Lesnick
Close
Sort by
Journal Articles

Ibrutinib-based therapy reinvigorates CD8 + T cells compared to chemoimmunotherapy: immune monitoring from the E1912 trial

Clinical Trials & Observations Brief Report
Despoina Papazoglou, Xin Victoria Wang, Tait D. Shanafelt, Connie E. Lesnick, Nikolaos Ioannou, Giulia De Rossi, Sylvia Herter, Marina Bacac, Christian Klein, Martin S. Tallman, Neil E. Kay, Alan G. Ramsay
Journal: Blood
Blood (2024) 143 (1): 57–63.
https://doi.org/10.1182/blood.2023020554
Published: 2024
Includes: Supplemental data
Journal Articles

Progression and survival of MBL: a screening study of 10 139 individuals

Susan L. Slager, Sameer A. Parikh, Sara J. Achenbach, Aaron D. Norman, Kari G. Rabe, Nicholas J. Boddicker, Janet E. Olson, Geffen Kleinstern, Connie E. Lesnick, Timothy G. Call, James R. Cerhan, Celine M. Vachon, Neil E. Kay, Esteban Braggio, Curtis A. Hanson, Tait D. Shanafelt
Journal: Blood
Blood (2022) 140 (15): 1702–1709.
https://doi.org/10.1182/blood.2022016279
Published: 2022
Includes: Supplemental data
Journal Articles

Measurable residual disease does not preclude prolonged progression-free survival in CLL treated with ibrutinib

Clinical Trials & Observations
Xin Victoria Wang, Curtis A. Hanson, Renee C. Tschumper, Connie E. Lesnick, Esteban Braggio, Elisabeth M. Paietta, Susan O’Brien, Jacqueline C. Barrientos, Jose Francisco Leis, Cong Christine Zhang, Steven E. Coutre, Paul M. Barr, Amanda F. Cashen, Anthony R. Mato, Avina K. Singh, Michael P. Mullane, Harry Erba, Richard Stone, Mark R. Litzow, Martin S. Tallman, Tait D. Shanafelt, Neil E. Kay
Journal: Blood
Blood (2021) 138 (26): 2810–2827.
https://doi.org/10.1182/blood.2020010146
Published: 2021
Includes: Supplemental data
Journal Articles

Prevalence and Overall Survival of Low Count Monoclonal B-Cell Lymphocytosis (LC-MBL): A Screening Study of 8,297 Individuals from the Mayo Clinic Biobank

Susan L. Slager, Sameer A. Parikh, Sara J. Achenbach, Geffen Kleinstern, Nicholas J. Boddicker, Aaron D. Norman, Kari G. Rabe, Connie E. Lesnick, Timothy G. Call, Janet E. Olson, James R. Cerhan, Neil E. Kay, Celine M. Vachon, Esteban Braggio, Curtis A. Hanson, Tait Shanafelt
Journal: Blood
Blood (2021) 138 (Supplement 1): 2632.
https://doi.org/10.1182/blood-2021-153320
Published: 2021
Journal Articles

The CLL International Prognostic Index predicts outcomes in monoclonal B-cell lymphocytosis and Rai 0 CLL

CME Clinical Trials & Observations
Sameer A. Parikh, Kari G. Rabe, Neil E. Kay, Timothy G. Call, Wei Ding, Jose F. Leis, Saad S. Kenderian, Eli Muchtar, Yucai Wang, Amber B. Koehler, Susan M. Schwager, Connie E. Lesnick, Geffen Kleinstern, Daniel Van Dyke, Curtis A. Hanson, Esteban Braggio, Susan L. Slager, Tait D. Shanafelt
Journal: Blood
Blood (2021) 138 (2): 149–159.
https://doi.org/10.1182/blood.2020009813
Published: 2021
Includes: Supplemental data
Journal Articles

Polygenic Risk Score and Risk of Chronic Lymphocytic Leukemia, Monoclonal B-Cell Lymphocytosis (MBL), and MBL Subtypes

Geffen Kleinstern, PhD, J. Brice Weinberg, MD, Sameer A. Parikh, MD, Esteban Braggio, PhD, Dennis P. Robinson, Aaron D. Norman, MPH, Kari G Rabe, Celine M. Vachon, PhD, Connie E. Lesnick, Timothy G. Call, MD, Danielle M. Brander, MD, Janet E. Olson, PhD, James R. Cerhan, MD PhD, Neil E. Kay, MD, Curtis A. Hanson, MD, Richard R. Furman, MD, Tait Shanafelt, MD, Susan L. Slager, PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 35–36.
https://doi.org/10.1182/blood-2020-136548
Published: 2020
Journal Articles

Ibrutinib-Based Therapy Improves Anti-Tumor T Cell Killing Function Allowing Effective Pairing with Anti-PD-L1 Immunotherapy Compared to Traditional FCR Chemoimmunotherapy; Implications for Therapy and Correlative Immune Functional Data from the Phase III E1912 Trial

Despoina Papazoglou, BSc, Connie E. Lesnick, Victoria Wang, Neil E. Kay, MD, Tait D. Shanafelt, MD, Alan G. Ramsay, BSc,MSc,PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 236.
https://doi.org/10.1182/blood-2018-99-118333
Published: 2018
Journal Articles

Association between the Risk of Low/High-Count Monoclonal B-Cell Lymphocytosis (MBL) and the Chronic Lymphocytic Leukemia (CLL) Polygenic Risk Score (PRS)

Geffen Kleinstern, PhD, Sara J. Achenbach, Dennis P. Robinson, Aaron D. Norman, Kari G. Chaffee, MS, Connie E. Lesnick, Sameer A. Parikh, MD, Timothy G. Call, MD, Janet E. Olson, PhD, James R. Cerhan, MD PhD, Neil E. Kay, MD, Curtis A. Hanson, MD, Tait D. Shanafelt, MD, Susan L. Slager, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 5538.
https://doi.org/10.1182/blood-2018-99-116414
Published: 2018